McPhail S, et al. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112 Suppl 1:S108–15.
Article
CAS
PubMed
Google Scholar
Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2013;22(1):4–11.
Article
PubMed
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Article
CAS
PubMed
Google Scholar
Cree IA. Improved blood tests for cancer screening: general or specific? BMC Cancer. 2011;11:499.
Article
PubMed
PubMed Central
Google Scholar
Lo YM, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–7.
Article
CAS
PubMed
Google Scholar
Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem. 2002;48(8):1186–93.
CAS
PubMed
Google Scholar
Lou X, et al. A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction. Int J Mol Med. 2015;35(1):72–80.
CAS
PubMed
Google Scholar
Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases. FEBS Lett. 2007;581(5):795–9.
Article
CAS
PubMed
Google Scholar
Lo YM. Noninvasive prenatal diagnosis: from dream to reality. Clin Chem. 2015;61(1):32–7.
Article
CAS
PubMed
Google Scholar
Zonta E, Nizard P, Taly V. Assessment of DNA integrity, applications for cancer research. Adv Clin Chem. 2015;70:197–246.
Article
PubMed
Google Scholar
Lo YM, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010;2(61):61ra91.
Article
CAS
PubMed
Google Scholar
Heitzer E, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133(2):346–56.
Article
CAS
PubMed
PubMed Central
Google Scholar
Uttley L, et al. Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review. EBioMedicine. 2016;10:164–73.
Article
PubMed
PubMed Central
Google Scholar
Page K, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kirkizlar E, et al. Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology. Transl Oncol. 2015;8(5):407–16.
Article
PubMed
PubMed Central
Google Scholar
Bettegowda C, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
Article
PubMed
PubMed Central
CAS
Google Scholar
Aung KL, et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J Mol Diagn. 2014;16(3):343–9.
Article
CAS
PubMed
Google Scholar
Board, R.E., et al., Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat, 2010. 120(2): p. 461–467.
Madhavan D, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat. 2014;146(1):163–74.
Article
CAS
PubMed
Google Scholar
Mead R, et al. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011;105(2):239–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tabernero J, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–48.
Article
CAS
PubMed
Google Scholar
Agostini M, et al. Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 2012;11(2–3):89–98.
Article
CAS
PubMed
Google Scholar
Hao TB, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zane M, et al. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): a non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 2013;67(8):723–30.
Article
CAS
PubMed
Google Scholar
Sikora K, et al. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2014:e136–41.
Gong B, et al. Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer. Oncol Lett. 2012;3(4):897–900.
CAS
PubMed
PubMed Central
Google Scholar
Zhong XY, et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet. 2007;276(4):327–31.
Article
CAS
PubMed
Google Scholar
Seefeld M, et al. Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors. Int J Biol Markers. 2008;23(2):69–73.
Article
CAS
PubMed
Google Scholar
Zanetti-Dallenbach RA, et al. Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers. 2007;22(2):95–9.
Article
CAS
PubMed
Google Scholar
Perrone F, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100(2):115–21.
CAS
PubMed
Google Scholar
Divella R, et al. PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis. Anticancer Res. 2008;28(1A):223–8.
CAS
PubMed
Google Scholar
Yang YJ, et al. Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction. Clin Invest Med. 2011;34(4):E238.
Article
CAS
PubMed
Google Scholar
Mazurek AM, et al. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 2016;54:36–41.
Article
CAS
PubMed
Google Scholar
Metz CH, et al. Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med. 2013;2(2):208–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Benesova L, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013;433(2):227–34.
Article
CAS
PubMed
Google Scholar
Crowley E, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.
Article
CAS
PubMed
Google Scholar
Salvi S, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther. 2016;9:6549–59.
Article
PubMed
PubMed Central
Google Scholar
Cree IA, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67(11):923–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bossuyt PM, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Clin Chem. 2015;61(12):1446–52.
Article
CAS
PubMed
Google Scholar
Ladabaum U, et al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomark Prev. 2013;22(9):1567–76.
Article
Google Scholar
Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.
Article
CAS
PubMed
Google Scholar
Kurihara S, et al. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg. 2015;50(12):2094–7.
Article
PubMed
Google Scholar
Kurtz DM, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125(24):3679–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Newman AM, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Belic J, et al. Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem. 2015;61(6):838–49.
Article
CAS
PubMed
Google Scholar
Andersen RF, et al. Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. Clin Chim Acta. 2015;439:97–101.
Article
CAS
PubMed
Google Scholar
Ellinger J, et al. CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol. 2009;182(1):324–9.
Article
CAS
PubMed
Google Scholar
Martinez-Galan J, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther. 2008;7(6):958–65.
Article
CAS
PubMed
Google Scholar
Kristensen LS, et al. Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. Oncotarget. 2012;3(4):450–61.
Article
PubMed
PubMed Central
Google Scholar
Page K, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One. 2013;8(10):e77963.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sorber L, et al. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn. 2017;19(1):162–8.
Article
CAS
PubMed
Google Scholar
De Mattos-Arruda L, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
Article
CAS
PubMed
PubMed Central
Google Scholar
Taback B, Saha S, Hoon DS. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients. Ann N Y Acad Sci. 2006;1075:197–203.
Article
CAS
PubMed
Google Scholar
Uchida J, et al. Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 2015;61(9):1191–6.
Article
CAS
PubMed
Google Scholar
Fernandez-Cuesta L, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine. 2016;10:117–23.
Article
PubMed
PubMed Central
Google Scholar
Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015;2:13.
Article
PubMed
PubMed Central
CAS
Google Scholar
Payne SR. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics. 2010;2(4):575–85.
Article
CAS
PubMed
Google Scholar
Church TR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–25.
Article
CAS
PubMed
Google Scholar
Potter NT, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014;60(9):1183–91.
Article
CAS
PubMed
Google Scholar
Toth K, et al. Circadian rhythm of methylated Septin 9, cell-free DNA amount and tumor markers in colorectal cancer patients. Pathol Oncol Res. 2016;
Zhao QT, et al. Diagnostic value of SHOX2 DNA methylation in lung cancer: a meta-analysis. Onco Targets Ther. 2015;8:3433–9.
PubMed
PubMed Central
Google Scholar
Begum S, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011;17(13):4494–503.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yi JM, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19(23):6544–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Diehl F, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lin JK, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol, 2014 21 Suppl. 4:S680–6.
Wang JY, et al. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28(7):721–6.
Article
PubMed
Google Scholar
Zhang Q, et al. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. Gynecol Oncol. 2013;130(1):132–9.
Article
CAS
PubMed
Google Scholar
Hauser S, et al. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res. 2013;33(10):4651–6.
CAS
PubMed
Google Scholar
Radpour R, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 2011;6(1):e16080.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303(1):21–8.
Article
CAS
PubMed
Google Scholar
Skrypkina I, et al. Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer. Dis Markers. 2016;2016:3693096.
Article
PubMed
PubMed Central
Google Scholar
Pack SC, et al. Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Color Dis. 2013;28(1):139–47.
Article
Google Scholar
Sikora K, et al. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2015;30(1):e136–41.
Article
PubMed
Google Scholar
Hsu HS, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer. 2007;110(9):2019–26.
Article
CAS
PubMed
Google Scholar
Couraud S, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res. 2014;20(17):4613–24.
Article
CAS
PubMed
Google Scholar
Hyman DM, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64–71.
Article
CAS
PubMed
Google Scholar
Thierry AR, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–5.
Article
CAS
PubMed
Google Scholar
Kim BH, et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J. 2015;56(3):634–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sharma G, et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010;87(3–4):83–91.
Article
CAS
PubMed
Google Scholar
Ibanez de Caceres I, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476–81.
Article
PubMed
Google Scholar
Melnikov A, et al. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn. 2009;11(1):60–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liggett, T.E., et al., Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol, 2011. 120(1): p. 113–20.
Hulbert A, et al. Early detection of lung cancer using DNA promoter Hypermethylation in plasma and sputum. Clin Cancer Res. 2016;
Chimonidou M, et al. CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem. 2013;46(3):235–40.
Article
CAS
PubMed
Google Scholar
Chen L, et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers. 2012;32(3):195–202.
Article
PubMed
PubMed Central
Google Scholar
Melson J, et al. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer. Int J Cancer. 2014;134(11):2656–62.
Article
CAS
PubMed
Google Scholar
Tian F, et al. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 2013;37(5):708–13.
Article
CAS
PubMed
Google Scholar
Powrozek T, et al. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients. Clin Transl Oncol. 2015;
Powrozek T, et al. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients. Clin Transl Oncol. 2016;18(4):398–404.
Article
CAS
PubMed
Google Scholar
Kloten V, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013;15(1):R4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chiappetta C, et al. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer. Clin Chim Acta. 2013;425:93–6.
Article
CAS
PubMed
Google Scholar
Szpechcinski A, et al. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 2016;374(2):202–7.
Article
CAS
PubMed
Google Scholar
Shao X, et al. Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett. 2015;10(6):3478–82.
PubMed
PubMed Central
Google Scholar
Andolfo I, et al. Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer. 2011;11:126.
Article
CAS
PubMed
PubMed Central
Google Scholar
Papadopoulou E, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann N Y Acad Sci. 2006;1075:235–43.
Article
CAS
PubMed
Google Scholar
Dumache R, et al. Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis. Clin Lab. 2014;60(5):847–52.
CAS
PubMed
Google Scholar
Minciu R, et al. Molecular diagnostic of prostate cancer from body fluids using methylation-specific PCR (MS-PCR) method. Clin Lab. 2016;62(6):1183–6.
CAS
PubMed
Google Scholar
Cassinotti E, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer. 2012;131(5):1153–7.
Article
CAS
PubMed
Google Scholar
Shan M, et al. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget. 2016;7(14):18485–94.
Article
PubMed
PubMed Central
Google Scholar
Huang G, et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med. 2014;52(6):899–909.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kuo YB, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–9.
Article
CAS
PubMed
Google Scholar
Spindler KL, et al. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015;10(4):e0108247.
Article
PubMed
PubMed Central
CAS
Google Scholar
Freidin MB, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem. 2015;61(10):1299–304.
Article
CAS
PubMed
Google Scholar
Sozzi G, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 1999;5(10):2689–92.
CAS
PubMed
Google Scholar
Eisenberger CF, et al. The detection of oesophageal adenocarcinoma by serum microsatellite analysis. Eur J Surg Oncol. 2006;32(9):954–60.
Article
CAS
PubMed
Google Scholar
Castagnaro A, et al. Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. Exp Lung Res. 2007;33(6):289–301.
Article
CAS
PubMed
Google Scholar
Andriani F, et al. Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer. 2004;108(1):91–6.
Article
CAS
PubMed
Google Scholar
Xia P, et al. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer. 2009;9:454.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kadam SK, Farmen M, Brandt JT. Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting. J Mol Diagn. 2012;14(4):346–56.
Article
CAS
PubMed
Google Scholar
Zaher ER, et al. Cell-free DNA concentration and integrity as a screening tool for cancer. Indian J Cancer. 2013;50(3):175–83.
Article
PubMed
Google Scholar
Danese E, et al. Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. Br J Cancer. 2013;109(3):807–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Skvortsova TE, et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006;94(10):1492–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hoque MO, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 2006;24(26):4262–9.
Article
CAS
PubMed
Google Scholar
Salvianti F, et al. Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma. Front Mol Biosci. 2015;2:76.
PubMed
Google Scholar
Rykova EY, et al. Investigation of tumor-derived extracellular DNA in blood of cancer patients by methylation-specific PCR. Nucleosides Nucleotides Nucleic Acids. 2004;23(6–7):855–9.
Article
CAS
PubMed
Google Scholar
Mohamed NA, et al. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J Gastroenterol. 2012;13(3):111–5.
Article
CAS
PubMed
Google Scholar
Zhang YJ, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13(8):2378–84.
Article
CAS
PubMed
Google Scholar
de Martino M, et al. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2012;118(1):82–90.
Article
CAS
PubMed
Google Scholar
deVos T, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337–46.
Article
CAS
PubMed
Google Scholar
Grutzmann R, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008;3(11):e3759.
Article
PubMed
PubMed Central
CAS
Google Scholar
Toth K, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9(12):e115415.
Article
PubMed
PubMed Central
CAS
Google Scholar
Powrozek T, et al. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jin P, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30(5):830–3.
Article
CAS
PubMed
Google Scholar
Warren JD, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kneip C, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011;6(10):1632–8.
Article
PubMed
Google Scholar
Weiss G, et al. Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 2017;12(1):77–84.
Article
PubMed
PubMed Central
Google Scholar
Chimonidou M, et al. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2013;59(1):270–9.
Article
CAS
PubMed
Google Scholar
Lange CP, et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One. 2012;7(11):e50266.
Article
CAS
PubMed
PubMed Central
Google Scholar